QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
OTCMKTS:AVCTF

Avacta Group (AVCTF) Stock Forecast, Price & News

$1.50
0.00 (0.00%)
(As of 06/5/2023 ET)
Compare
Today's Range
$1.50
▼
$1.50
50-Day Range
$1.25
▼
$2.05
52-Week Range
$1.25
▼
$2.29
Volume
N/A
Average Volume
1,040 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesShort Interest

AVCTF stock logo

About Avacta Group (OTCMKTS:AVCTF) Stock

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Receive AVCTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

AVCTF Stock News Headlines

June 5, 2023 | lse.co.uk
Avacta sees shares rise on new equity payment for South Korea venture
June 1, 2023 | finance.yahoo.com
Avacta Group's (LON:AVCT) investors will be pleased with their solid 218% return over the last five years
June 5, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 5, 2023 | finance.yahoo.com
Avacta Group Plc's (LON:AVCT) Business Is Trailing The Industry But Its Shares Aren't
May 2, 2023 | americanbankingnews.com
Avacta Group Plc (OTCMKTS:AVCTF) Short Interest Down 8.0% in April
April 7, 2023 | marketwatch.com
Avacta Group's Shares Rise on US Site Openings for Cancer Study Patient Enrolment
April 6, 2023 | lse.co.uk
Avacta doses first patient in fifth cohort of AVA6000 phase 1 study
April 6, 2023 | lse.co.uk
Avacta opens first two clinical investigator sites in US for AVA6000
June 5, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
April 5, 2023 | finance.yahoo.com
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
April 1, 2023 | finance.yahoo.com
Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
March 31, 2023 | finanznachrichten.de
Avacta Group plc: Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
March 31, 2023 | finance.yahoo.com
Avacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 55% of the company
January 17, 2023 | benzinga.com
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
December 1, 2022 | finance.yahoo.com
Investors in Avacta Group (LON:AVCT) have made a incredible return of 538% over the past three years
September 11, 2022 | fool.co.uk
Avacta Group
September 5, 2022 | finance.yahoo.com
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
September 1, 2022 | finance.yahoo.com
Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort
May 3, 2022 | finance.yahoo.com
Even though Avacta Group (LON:AVCT) has lost UK£39m market cap in last 7 days, shareholders are still up 304% over 3 years
April 13, 2022 | finance.yahoo.com
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake
January 18, 2022 | finance.yahoo.com
What You Need To Know About Avacta Group Plc's (LON:AVCT) Investor Composition
November 29, 2021 | finance.yahoo.com
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
November 19, 2021 | finance.yahoo.com
Avacta Group (LON:AVCT) shareholder returns have been enviable, earning 486% in 3 years
July 1, 2021 | finanznachrichten.de
Avacta Group plc: Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
June 29, 2021 | markets.businessinsider.com
Avacta : AffiDX Antigen Lateral Flow Test Detects Delta Variant Of SARS-CoV-2 Virus
June 29, 2021 | lse.co.uk
AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs
June 29, 2021 | finance.yahoo.com
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
See More Headlines

AVCTF Price History

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Miscellaneous Commercial Services
Sub-Industry
N/A
Sector
Business Services
Current Symbol
OTCMKTS:AVCTF
CUSIP
N/A
CIK
N/A
Web
www.avacta.com
Phone
44.1904.21.7070
Fax
N/A
Employees
123
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. David Alastair Smith
    CEO & Exec. Director
  • Mr. Tony Gardiner (Age 51)
    CFO, Company Sec. & Exec. Director
    Comp: $310.25k
  • Ms. Emma Wright
    Group In-House Counsel
  • Mr. Michael Vinegrad
    Group Communications Director
  • Dr. Matt Johnson
    Chief Scientific Officer of Diagnostics
  • Dr. Neil Bell (Age 64)
    Chief Devel. Officer of Therapeutics
  • Dr. Fiona McLaughlin FSB (Age 52)
    Ph.D., Chief Scientific Officer of Therapeutics Division
  • Mr. Marc Green
    Head of Product Devel. - Diagnostics
  • Gemma Wilson
    Head of QA/RA - Diagnostics
  • Mr. Petros Sarantos
    Head of Product Management - Diagnostics

Key Competitors

View All Competitors













AVCTF Stock - Frequently Asked Questions

How have AVCTF shares performed in 2023?

Avacta Group's stock was trading at $1.5799 on January 1st, 2023. Since then, AVCTF stock has decreased by 5.1% and is now trading at $1.50.
View the best growth stocks for 2023 here.

What is Avacta Group's stock symbol?

Avacta Group trades on the OTCMKTS under the ticker symbol "AVCTF."

How do I buy shares of Avacta Group?

Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avacta Group's stock price today?

One share of AVCTF stock can currently be purchased for approximately $1.50.

How many employees does Avacta Group have?

The company employs 123 workers across the globe.

How can I contact Avacta Group?

Avacta Group's mailing address is Thorp Arch Estate, Leeds, West Yorkshire. The official website for the company is www.avacta.com. The company can be reached via phone at 44.1904.21.7070.

This page (OTCMKTS:AVCTF) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -